PMID- 28915624
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20170925
LR  - 20181113
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 34
DP  - 2017 Aug 22
TI  - Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced 
      NSCLC patients with EGFR-sensitive mutations.
PG  - 56714-56725
LID - 10.18632/oncotarget.18083 [doi]
AB  - We conducted this retrospective study to investigate whether microwave ablation 
      (MWA) of primary tumor sites plus epidermal growth factor receptor-tyrosine 
      kinase inhibitors (EGFR-TKIs) could improve survival in advanced non small cell 
      lung cancer (NSCLC) with EGFR mutations. MWA was conducted at the primary tumor 
      sites, followed by EGFR-TKIs in the MWA plus EGFR-TKIs group. EGFR-TKIs were 
      administered until disease progression or intolerable toxicity. The primary 
      endpoint was progression-free survival (PFS); secondary endpoints were overall 
      survival (OS) and objective response rate (ORR). A total of 58 patients were 
      recruited, including 34 in the MWA plus EGFR-TKIs group and 24 in the EGFR-TKIs 
      group. No significant difference in ORR was observed with MWA treatment (61.8% 
      vs. 45.8%, p = 0.230). Patients treated with MWA plus EGFR-TKIs failed to show 
      superior survival in either PFS (13.2 months vs. 11.6 months, p = 0.640) or OS 
      (39.8 months vs. 20.4 months, p = 0.288). MWA was not an independent prognostic 
      factor for PFS or OS. MWA of primary tumor sites plus EGFR-TKIs demonstrated no 
      survival advantage compared with EGFR-TKIs alone in advanced NSCLC patients with 
      EGFR sensitive mutations. MWA should not be recommended for unselected patients 
      with EGFR-sensitive mutations.
FAU - Wei, Zhigang
AU  - Wei Z
AD  - Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong 
      University, Jinan 250021, Shandong Province, China.
FAU - Ye, Xin
AU  - Ye X
AD  - Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong 
      University, Jinan 250021, Shandong Province, China.
FAU - Yang, Xia
AU  - Yang X
AD  - Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong 
      University, Jinan 250021, Shandong Province, China.
FAU - Zheng, Aimin
AU  - Zheng A
AD  - Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong 
      University, Jinan 250021, Shandong Province, China.
FAU - Huang, Guanghui
AU  - Huang G
AD  - Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong 
      University, Jinan 250021, Shandong Province, China.
FAU - Li, Wenhong
AU  - Li W
AD  - Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong 
      University, Jinan 250021, Shandong Province, China.
FAU - Wang, Jiao
AU  - Wang J
AD  - Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong 
      University, Jinan 250021, Shandong Province, China.
FAU - Han, Xiaoying
AU  - Han X
AD  - Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong 
      University, Jinan 250021, Shandong Province, China.
FAU - Meng, Min
AU  - Meng M
AD  - Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong 
      University, Jinan 250021, Shandong Province, China.
FAU - Ni, Yang
AU  - Ni Y
AD  - Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong 
      University, Jinan 250021, Shandong Province, China.
LA  - eng
PT  - Journal Article
DEP - 20170523
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5593595
OTO - NOTNLM
OT  - epidermal growth factor receptor
OT  - microwave ablation
OT  - non-small cell lung cancer
OT  - progression free survival
OT  - tyrosine kinase inhibitors
COIS- CONFLICTS OF INTEREST No conflicts of interest exists.
EDAT- 2017/09/17 06:00
MHDA- 2017/09/17 06:01
PMCR- 2017/08/22
CRDT- 2017/09/17 06:00
PHST- 2017/03/27 00:00 [received]
PHST- 2017/04/27 00:00 [accepted]
PHST- 2017/09/17 06:00 [entrez]
PHST- 2017/09/17 06:00 [pubmed]
PHST- 2017/09/17 06:01 [medline]
PHST- 2017/08/22 00:00 [pmc-release]
AID - 18083 [pii]
AID - 10.18632/oncotarget.18083 [doi]
PST - epublish
SO  - Oncotarget. 2017 May 23;8(34):56714-56725. doi: 10.18632/oncotarget.18083. 
      eCollection 2017 Aug 22.